Neumora Therapeutics (NMRA) Long-Term Investments (2022 - 2024)

Neumora Therapeutics has reported Long-Term Investments for 3 years, with the latest figure at $302000.0 in Q1 2024.

• For the quarter ending Q1 2024, Long-Term Investments changed N/A year-over-year to $302000.0; the trailing twelve-month figure through Mar 2024 stood at $302000.0 (changed N/A YoY), and the FY2023 full-year result was $9.8 million, down 58.13% from the prior year.
• Long-Term Investments for Q1 2024 stood at $302000.0, down from $9.8 million in the prior quarter.
• The five-year high for Long-Term Investments was $23.5 million in Q4 2022, with the low at $302000.0 in Q1 2024.
• Average Long-Term Investments over 3 years is $10.9 million, with a median of $9.9 million recorded in 2023.
• Peak annual rise in Long-Term Investments reached 58.13% in 2023, while the deepest fall reached 58.13% in 2023.
• Tracing NMRA's Long-Term Investments over 3 years: stood at $23.5 million in 2022, then sank by 58.13% to $9.8 million in 2023, then plunged by 96.93% to $302000.0 in 2024.
• The last three Long-Term Investments figures came in at $302000.0 (Q1 2024), $9.8 million (Q4 2023), and $9.9 million (Q3 2023), per Business Quant data.

Peer Comparison